Skip to content

Music-Augmented Rhythmic Gait Training in Multiple Sclerosis

Music-Augmented Versus Non-Music Technology-Based Rhythmic Gait Training in Multiple Sclerosis: A Randomized Controlled Trial of Gait Performance and Clinical Outcomes

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07399262
Enrollment
32
Registered
2026-02-10
Start date
2026-01-20
Completion date
2026-07-30
Last updated
2026-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis, Rehabilitation

Keywords

Multiple Sclerosis, Rhythmic Gait Training, Music-Based Exercise, Telerehabilitation, Gait Performance

Brief summary

This randomized controlled trial aims to compare the effects of technology-based rhythmic gait training performed with and without music on walking performance and clinical outcomes in individuals with multiple sclerosis (MS). Thirty-two participants with mild to moderate disability will be randomly assigned to either a music-assisted rhythmic gait training group or a non-music control group, with both interventions delivered via telerehabilitation. Outcomes related to gait performance, balance, fatigue, and cognitive function will be assessed before and after a four-week intervention period.

Detailed description

Multiple sclerosis (MS) is a chronic, inflammatory, and demyelinating disease of the central nervous system that leads to impairments in motor and cognitive functions, with gait disturbances being among the most common and disabling symptoms. Walking impairments in individuals with MS substantially reduce quality of life and are frequently accompanied by balance deficits, fatigue, and decreased functional capacity, ultimately limiting independence in daily activities. Recent evidence suggests that rhythmic auditory stimulation and music-based gait training can enhance motor control and walking performance by providing external temporal cues that facilitate movement coordination. In parallel, telerehabilitation has emerged as an effective and accessible rehabilitation approach, enabling supervised exercise delivery while reducing barriers related to transportation, cost, and long-term adherence. In this randomized controlled trial, a total of 32 individuals with MS who have an Expanded Disability Status Scale (EDSS) score between 0 and 4 and a definite diagnosis according to the McDonald criteria will be recruited. Participants will be randomly allocated into two groups using computer-generated randomization. The intervention group (Group A) will perform rhythmic gait exercises accompanied by music, whereas the control group (Group B) will perform the same exercises without music. Both interventions will be delivered in a telerehabilitation format under the supervision of a physiotherapist. The intervention program will last four weeks, with training sessions conducted four days per week. Primary and secondary outcome measures assessing walking performance, balance, fatigue, and cognitive function will be administered before and after the intervention period. The primary objective of this study is to comparatively evaluate the effects of technology-based, music-assisted rhythmic gait training on motor outcomes in individuals with MS and to contribute high-quality scientific evidence to an area that remains underrepresented in the current rehabilitation literature.

Interventions

OTHERBreathing and General Mobility Exercises

rticipants will perform standardized breathing exercises and general mobility exercises. These exercises will be delivered in the same telerehabilitation format and supervised by a physiotherapist.

OTHERMusic-Assisted Rhythmic Gait Training

Participants will perform rhythmic gait training accompanied by music. The training will be delivered via telerehabilitation with real-time supervision through videoconferencing. Sessions will be conducted four days per week for four weeks. Gait training will be guided using instructional videos presented with music accompaniment.

OTHERRhythmic Gait Training Without Music

Participants will perform the same rhythmic gait training program without music. The training will be delivered via telerehabilitation with real-time supervision through videoconferencing. Sessions will be conducted four days per week for four weeks. Gait training will be guided using instructional videos presented without music (silent).

Sponsors

Biruni University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

This study is a two-arm, parallel-group, randomized controlled trial comparing music-assisted rhythmic gait training with non-music rhythmic gait training, conducted without masking due to the nature of the interventions.

Intervention model description

This study is a two-arm, parallel-group, randomized controlled trial comparing music-assisted rhythmic gait training with non-music rhythmic gait training, conducted without masking due to the nature of the interventions.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Expanded Disability Status Scale (EDSS) score between 0 and 4.0 Access to the internet via a high-speed smartphone or computer A score of at least 21 on the Montreal Cognitive Assessment (MoCA) Functional Ambulation Scale score of Stage 3 or higher

Exclusion criteria

* Presence of hearing or visual impairments Current participation in any structured exercise program Presence of other neurological, cardiovascular, or orthopedic disorders History of MS relapse or change in disease-modifying treatment within the last 6 months Physical conditions preventing safe participation in the exercise program Comorbid conditions that adversely affect oxygen transport (e.g., severe anemia, peripheral arterial disease)

Design outcomes

Primary

MeasureTime frameDescription
Gait SpeedBaseline and immediately after interventionWalking speed is the primary outcome measure of the study and will be assessed using the Timed 25-Foot Walk Test (T25FW). In this test, participants are instructed to walk a distance of 7.62 m (25 feet) as quickly and safely as possible, without running. The completion time is recorded in seconds. Two trials are performed, and the average of the two trials is recorded as the T25FW score. The T25FW is one of the most well-established and widely used measures for assessing gait impairment and walking speed in individuals with multiple sclerosis

Secondary

MeasureTime frameDescription
Two Minute Walk TestBaseline and immediately after interventionThe Two-Minute Walk Test (2MWT) will be used to assess functional walking capacity and treatment response. The total distance walked within two minutes is recorded in meters. Vital signs are measured before and after the test. In this study, the 2MWT is preferred over the 6-Minute Walk Test due to its practicality, feasibility, and validated use in individuals with MS without inducing excessive fatigue
Timed Up and Go TestBaseline and immediately after interventionIn the Timed Up and Go Test, participants are instructed to stand up from a seated position, walk a distance of 3 meters, turn around a reference object, return to the chair, and sit down. The time required to complete the task is recorded in seconds. The test is performed three times, and the average time is used for analysis
Step LengthBaseline and immediately after interventionKinovea® software (version 0.8.15) is used to perform objective and quantitative kinematic and spatiotemporal gait analysis from video recordings. The software enables the analysis of parameters such as step length, stride length, base of support, step width, cadence, walking speed, and step time (37). In this study, gait will be recorded using a camera positioned in the sagittal plane while participants walk a distance of 3 meters. Colored markers will be placed on the right and left heels to facilitate identification in the video recordings. Several gait cycles will be captured and analyzed independently using Kinovea software to determine step length (distance between consecutive heel strikes of opposite limbs), stride length (distance between consecutive heel strikes of the same limb), cadence (steps per minute), and bilateral step lengths (38-40). Walking speed (V) will be calculated using the formula:
Stride LengthBaseline and immediately after interventionKinovea® software (version 0.8.15) is used to perform objective and quantitative kinematic and spatiotemporal gait analysis from video recordings. The software enables the analysis of parameters such as step length, stride length, base of support, step width, cadence, walking speed, and step time (37). In this study, gait will be recorded using a camera positioned in the sagittal plane while participants walk a distance of 3 meters. Colored markers will be placed on the right and left heels to facilitate identification in the video recordings. Several gait cycles will be captured and analyzed independently using Kinovea software to determine step length (distance between consecutive heel strikes of opposite limbs), stride length (distance between consecutive heel strikes of the same limb), cadence (steps per minute), and bilateral step lengths (38-40). Walking speed (V) will be calculated using the formula:
Walking SpeedBaseline and immediately after interventionKinovea® software (version 0.8.15) is used to perform objective and quantitative kinematic and spatiotemporal gait analysis from video recordings. The software enables the analysis of parameters such as step length, stride length, base of support, step width, cadence, walking speed, and step time (37). In this study, gait will be recorded using a camera positioned in the sagittal plane while participants walk a distance of 3 meters. Colored markers will be placed on the right and left heels to facilitate identification in the video recordings. Several gait cycles will be captured and analyzed independently using Kinovea software to determine step length (distance between consecutive heel strikes of opposite limbs), stride length (distance between consecutive heel strikes of the same limb), cadence (steps per minute), and bilateral step lengths (38-40). Walking speed (V) will be calculated using the formula:
Modified Fatigue Impact ScaleBaseline and immediately after interventionThe Modified Fatigue Impact Scale (MFIS) is a 21-item questionnaire designed to assess the impact of fatigue on physical, cognitive, and psychosocial functioning (41). Each item is scored on a 5-point Likert scale ranging from 0 (no problem) to 4 (severe problem). The total score ranges from 0 to 84, with higher scores indicating greater fatigue severity. Subscale scores for physical, cognitive, and psychosocial domains are calculated and summed to obtain the total score.
The Four Square Step TestBaseline and immediately after interventionThe Four Square Step Test evaluates the ability to change direction while stepping. Participants begin in Square 1 (upper left) and follow a predefined stepping sequence clockwise (Squares 1-2-4-3) and then counterclockwise (Squares 3-4-2-1). The physiotherapist demonstrates the test and allows practice trials if needed. If the participant loses balance, touches the assistive device, or fails to complete the sequence, the test is repeated. Two trials are recorded, and the best performance time is used for analysis. Timing begins when the first foot contacts Square 2 and ends when both feet return to Square 1
BICAMS BatteryBaseline and immediately after interventionThe BICAMS battery includes the Symbol Digit Modalities Test (SDMT), California Verbal Learning Test-Second Edition (CVLT-II), and Brief Visuospatial Memory Test-Revised (BVMT-R). The battery was recommended in 2012 for monitoring cognitive function in individuals with MS, and its Turkish validity and reliability were established in 2017

Countries

Turkey (Türkiye)

Contacts

CONTACTGüzin Kaya Aytutuldu
guzinkaya14@gmail.com05366265884
PRINCIPAL_INVESTIGATORGuzin Kaya Aytutuldu

Biruni University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026